EPCAM and prostate cancer: We also investigated CTC levels using two CTC enrichment technologies, the EpCAM‐based CellSearch® system (approved by the Food and Drug Administration (FDA) for the prognostic assessment of CTCs in patients with metastatic breast, colon and prostate cancer [46, 47, 48]) and the microfluidic epitope‐independent‐based method Parsortix system to complete our liquid biopsy approach.